18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT | Semantic Scholar (2024)

Lower-limb imaging did not change the metastatic status of disease or significantly affect the therapeutic approach, however, if multimetastatic patients present relevant symptoms for lower-limB metastasis, it could be beneficial to consider including lower- Limb imaging for possible palliative therapies.

Performance of 18F-Fluciclovine PET/CT in prostate cancer patients with multiple treatment failures and PSAPet ≤ 0.5 ng/mL was acceptable particularly in patients with PSAPET ≥ 0.3 ng/L, CRPC, initial GS ≥ 8 or T3-T4.

This research presents a novel and scalable approach to personalized medicine that combines radiotherapy and nuclear medicine and aims to provide real-time information about the dynamic response of the immune system to chemotherapy.

In the presence of low PSA level in PC patients after definitive treatment, 18F-DCFPyL PET/CT is most beneficial in detection of disease in patients with GS of 8 or higher at the time of diagnosis, and the ones who have history of ADT only, or ADT plus chemotherapy.

An up-to-date summary of chronologically existing diagnostic approaches for PCa, as well as their potential to improve clinically significant PCa (csPCa) diagnosis and to reduce the proliferation and monitoring of PCa are provided.

The efficacy of the traditional imaging modalities as well as the novel imaging techniques in detecting metastatic prostate cancer are discussed.

...

...

Preliminary results indicate that anti-3-18F-FACBC may be superior to 11C-choline for the identification of disease recurrence in the setting of biochemical failure.

Combined FACBC PET/CT and T2-weighted MR imaging enable more accurate localization of prostate cancer lesions than either modality alone, and shows higher uptake in intraprostatic tumor foci than in normal prostate tissue.

Fluciclovine shows high uptake in prostate cancer deposits and appears safe for use in humans, and the production is robust and the formulation stable in vivo.

Anti-3-(18)F-FACBC PET/CT was more sensitive than (111)In-capromab pendetide SPECT/CT in the detection of recurrent prostate carcinoma and is highly accurate in the differentiation of prostatic from extraprostatic disease.

The observed effective doses suggest the feasibility of [11C]choline PET for human studies, but rat data may underestimate the effective dose, suggesting that clinical measurements are needed for a more detailed estimation.

...

...